

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Core Oncology, Inc

Application No./Patent No.: 10/828,539 Filed/Issue Date: April 20, 2004

Entitled: Echogenic Medical Device

Core Oncology, Inc, a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____%)

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
- OR
- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Stanley L. Mills To: Mills Biopharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel 017489, Frame 0512, or for which a copy thereof is attached.
2. From: Mills Biopharmaceuticals, Inc. To: Coloplast A/S
The document was recorded in the United States Patent and Trademark Office at Reel 018490, Frame 0831, or for which a copy thereof is attached.
3. From: Coloplast A/S To: Mills Biopharmaceuticals, Inc
The document was recorded in the United States Patent and Trademark Office at Reel 019000, Frame 0117, or for which a copy thereof is attached.

☒ Additional documents in the chain of title are listed on a supplemental sheet.

☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Chris Nicholson

Signature

Chris Nicholson

Printed or Typed Name

Chief Financial Officer, Core Oncology, Inc.

Title

2/10/2008

Date

(206) 926-2301

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Supplemental Sheet to Statement Under 37 CFR 3.73(b):
Additional documents in the chain of title:

Patent Application No. 10/828,539

Filing Date: April 20, 2004

4. From: Mills Biopharmaceuticals, Inc. To: Core Oncology, Inc.

The document was recorded in the United States Patent and Trademark Office at

Reel

1 019399, Frame 0589, or for which a copy thereof is attached.

5. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

6. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.